natgillin/translations-raw huggingface dataset:
Patienterne skal antikoagulansbehandles relevant i henhold til kliniske retningslinjer for AF.
Patients should be appropriately anti-coagulated as per clinical AF guidelines.
Patienterne skal behandles med kun én formulering af tacrolimus i overensstemmelse med det daglige dosisregime; ændringer i formulering eller regime bør kun ske under nøje supervision fra en speciallæge i transplantation (se pkt.
Patients should be maintained on a single formulation of tacrolimus with the corresponding daily dosing regimen; alterations in formulation or regimen should only take place under the close supervision of a transplant specialist (see sections 4.2 and 4.8).
Patienterne skal behandles med Perjeta og trastuzumab indtil sygdomsprogression eller uacceptabel toksicitet.
Patients should be treated with Perjeta and trastuzumab until disease progression or unmanageable toxicity.
Patienterne skal desuden gives dexamethason (et steroid) som hjælp til at regulere nogle af lægemidlets bivirkninger.
The patient should also receive dexamethasone (a steroid) to help control some of the medicine’s side effects.
Patienterne skal dog tilrådes at udsætte behandlede områder mindst muligt for sollys eller andet ultraviolet (UV) lys (se afsnit 5.3).
However, patients must be cautioned to minimise exposure of treated areas to sunlight or other ultraviolet (UV) light. (see section 5.3).
Patienterne skal drikke rigeligt med vand, mens de er i behandling.
Patients should drink plenty of water while on treatment.
Patienterne skal efter operation behandles med adjuverende trastuzumab for at gennemføre 1 års behandling (se pkt.
Following surgery, patients should be treated with adjuvant trastuzumab to complete 1 year of treatment (see section 5.1).
Patienterne skal evalueres efter to uger, og behandlingen skal stoppes for patienter, som ikke fremviser en forbedring.
Patients should be evaluated after two weeks and treatment should be stopped for those who have not shown an improvement.
Patienterne skal fortsætte med at trække vejret ind, selv efter at der høres et ”klik” fra inhalatoren.
Patients should keep breathing in, even after they have heard the inhaler "click".
Patienterne skal fortælle det til deres læge, hvis de har en svær leversygdom, før de påbegynder behandling.
Patients should inform their doctor before they start treatment if they have severe hepatic disease.
Patienterne skal følges nøje fra behandlingens indledning, og dosen skal titreres, indtil en effektiv dosis opnås, og bekræftes ved behandling af to på hinanden følgende episoder med gennembrudssmerter.
From treatment initiation, patients should be closely followed and the dose titrated until an effective dose is reached and confirmed for two consecutively treated episodes of BTP.
Patienterne skal først tage peginterferon alfa og ribavirin i fire uger, hvorefter de skal tilføje Victrelis til behandlingen i op til 44 uger, afhængigt af flere faktorer, såsom patientens tidligere behandling og resultaterne af blodprøver under behandlingen.
The patients must first take peginterferon alfa and ribavirin for four weeks, after which they will add Victrelis to the treatment for up to 44 weeks, depending on several factors such as the patient’s previous treatment and results of blood tests during treatment.
Patienterne skal have adækvat antitrombotisk profylakse, da der kan forekomme trombotiske og vaskulære hændelser hos kirurgiske patienter, specielt hos patienter med underliggende kardiovaskulær sygdom.
Patients should receive adequate antithrombotic prophylaxis, as thrombotic and vascular events may occur in surgical patients, especially in those with underlying cardiovascular disease.
Patienterne skal have at vide, at de ved pludseligt opstået høretab skal holde op med at tage PDE5- hæmmere, herunder avanafil, og straks søge lægehjælp.
Patients should be advised to stop taking PDE5 inhibitors, including avanafil, and seek prompt medical attention in the event of sudden decrease or loss of hearing.
Patienterne skal have at vide, at det er nødvendigt hver dag at tage Viramune som ordineret.
Patients should be advised of the need to take Viramune every day as prescribed.
Patienterne skal have besked på at søge læge, hvis der opstår tegn/symptomer, der tyder på lysfølsomhed, under eller efter terapi med porfimer.
Patients should be instructed to seek medical advice if signs/symptoms suggestive of photosensitivity occur during or after therapy with porfimer.
Patienterne skal have information om, at Oncaspar ikke må anvendes samtidigt med andre lægemidler, der medfører en øget risiko for blødninger (se "Brug af anden medicin sammen med Oncaspar").
It should be explained to patients that Oncaspar should not be used at the same time as other medicines associated with an increased risk of bleeding (see “Other medicines and Oncaspar”).
Patienterne skal have intravenøs væsketerapi i hele den 5 dage lange periode med administration af clofarabin for at nedsætte virkningerne af tumorlyse og andre hændelser.
Patients should receive intravenous fluids throughout the 5 day clofarabine administration period to reduce the effects of tumour lysis and other events.
Patienterne skal have udleveret et patientinformationskort.
Patients will also be provided with a patient alert card.
Patienterne skal have undersøgt, ører næse og hals undersøgt med regelmæssige mellemrum og ved forekomst af kliniske symptomer for at udelukke sådanne potentielle komplikationer eller for at iværksætte en passende behandling.
That patients should have examinations of the ears, nose and throat periodically and at the occurrence of clinical symptoms to rule out such potential complications or to initiate appropriate treatment.
Patienterne skal ikke tage en dobbeltdosis (to doser på samme tid) for at gøre det ud for den glemte dosis.
Patients should not take a double dose (two doses at the same time) to make up for a forgotten dose.
Patienterne skal indlægges i behandlingens begyndelse på grund af sygdomssymptomer og for at sikre tilstrækkelig overvågning.
Patients must be hospitalised at the beginning of treatment due to symptoms of disease and to ensure adequate monitoring.
Patienterne skal informeres m at rådføre sig med deres læge før rejse mellem forskellige tidszoner, da dette kan medføre, at patienten skal tage insulin og mad på andre tidspunkter.
Before travelling between different time zones, the patient should seek the doctor’s advice since this may mean that the patient has to take the insulin and meals at different times.
Patienterne skal informeres om at afbryde behandlingen og søge læge, hvis de får alvorlig obstipation, der varer mere end 4 dage.
If patients develop severe constipation for a duration of more than 4 days, they should be instructed to stop the treatment and seek medical attention.
Patienterne skal informeres om at fortsætte behandlingen og søge læge, hvis astmasymptomerne forbliver ukontrollerede eller forværres efter påbegyndelse af BiResp Spiromax- behandling.
Patients should be asked to continue treatment but to seek medical advice if asthma symptoms remain uncontrolled or worsen after initiation with BiResp Spiromax.
Patienterne skal informeres om at fortsætte behandlingen og søge læge, hvis astmasymptomerne forbliver ukontrollerede eller forværres efter påbegyndelse af Budesonid/Formoterol Teva-behandling.
Patients should be asked to continue treatment but to seek medical advice if asthma symptoms remain uncontrolled or worsen after initiation with Budesonide/Formoterol Teva .
Patienterne skal informeres om at fortsætte behandlingen og søge læge, hvis astmasymptomerne forbliver ukontrollerede eller forværres efter påbegyndelse af DuoResp Spiromax- behandling.
Patients should be asked to continue treatment but to seek medical advice if asthma symptoms remain uncontrolled or worsen after initiation with DuoResp Spiromax.
Patienterne skal informeres om at fortsætte behandlingen, men at søge læge, hvis astmasymptomerne bliver ved med at være ukontrollerede, eller hvis de forværres, efter behandling Airexar Spiromax påbegyndes.
Patients should be asked to continue treatment but to seek medical advice if asthma symptoms remain uncontrolled or worsen after initiation on Aerivio Spiromax.
Patienterne skal informeres om at indberette nye eller usædvanlige smerter i lår, hofte eller lyske under behandling med Prolia.
During Prolia treatment, patients should be advised to report new or unusual thigh, hip, or groin pain.
Patienterne skal informeres om at indberette nye eller usædvanlige smerter i lår, hofte eller lyske under behandling med XGEVA.
During XGEVA treatment, patients should be advised to report new or unusual thigh, hip, or groin pain.
Patienterne skal informeres om at kontakte deres læge, hvis den kraftige blødning fortsætter.
Should the excessive bleeding persist, patients should notify their physician.
Patienterne skal informeres om at kontakte sygeplejersken eller lægen med det samme, hvis de får et eller flere af ovenstående eller symptomer.
Patients should be instructed to inform their nurse or physician immediately if they experience any of the above signs or symptoms.
Patienterne skal informeres om at kontakte sygeplejersken eller lægen med det samme, hvis de får et eller flere af ovenstående symptomer.
Patients should be instructed to inform their nurse or physician immediately if they experience any of the above signs or symptoms.
Patienterne skal informeres om at seponere behandlingen og søge læge, hvis de får symptomer, der kan tyde på spasmer i sphincter Oddi, såsom akut forværring af abdominalsmerter (fx akutte epigastriske eller biliære [dvs. højre øvre kvadrant] smerter), som kan stråle ud til ryg eller skulder, med eller uden kvalme og opkastning.
Patients should be instructed to stop the treatment and seek medical attention if they experience symptoms suggestive of sphincter of Oddi spasm such as acute worsening of abdominal pain (e.g. acute epigastric or biliary [i.e., right upper quadrant] pain) that may radiate to the back or shoulder, with or without nausea and vomiting.
Patienterne skal informeres om straks at kontakte lægen, hvis de får disse symptomer, navnlig hvis de hidtil har tålt metformin godt.
Patients should be instructed to notify these signs immediately to their physicians if they occur, notably if patients had a good tolerance to metformin before.
Patienterne skal informeres om vigtigheden af ikke at overskride den anbefalede dosering.
Patients should be advised of the importance not to exceed the recommended dose.
Patienterne skal informeres om, at Airexar Spiromax skal bruges dagligt for at få optimal fordel af præparatet, også i perioder uden symptomer.
Patients should be made aware that Aerivio Spiromax must be used daily for optimum benefit, even when asymptomatic.
Patienterne skal informeres om, at behandlingen med Torisel kan være forbundet med en øgning af blodglucoseniveauet hos patienter med eller uden diabetes.
Patients should be advised that treatment with Torisel may be associated with an increase in blood glucose levels in diabetic and non-diabetic patients.
Patienterne skal informeres om, at de ikke må sluge tørrekapslen i tabletbeholderen.
Patients should be advised not to swallow the desiccant capsule found in the bottle.
Patienterne skal informeres om, at de omgående skal konsultere en læge, hvis der pludseligt opstår en synsdefekt (se pkt 4.3).
The patient should be advised that in case of sudden visual defect, to consult a physician immediately (see section 4.3).
Patienterne skal informeres om, at de straks skal kontakte sundhedspersonalet, hvis de oplever træthed, svaghed, appetitløshed, kvalme og opkastning, gulsot eller unormalt farvet fæces.
Patients should be instructed to consult their healthcare professional without delay if they have onset of fatigue, weakness, lack of appetite, nausea and vomiting, jaundice or discoloured faeces.
Patienterne skal informeres om, at overfølsomhedsreaktioner kan forekomme på dagen eller dagen efter infusionen, og de skal informeres om potentielle tegn og symptomer og om risikoen for tilbagefald.
Patients should be advised that hypersensitivity reactions are possible on the day of, or the day after infusion, and be informed of potential signs and symptoms and the possibility of recurrence.
Patienterne skal informeres om, hvilke symptomer der er karakteristiske for pancreatitis, som kan blive fatal uden behandling: Vedvarende mavesmerter, muligvis svære og med udstråling mod ryggen.
Patients should be informed of the characteristic symptom of pancreatitis that, if left untreated, could become fatal: persistent abdominal pain that could be severe, which may radiate to the back.
Patienterne skal informeres om:
Patients should be instructed:
Patienterne skal instrueres i altid at kontrollere insulinetiketten før hver injektion for at undgå utilsigtet forveksling af de to styrker af Tresiba såvel som andre insulinpræparater.
Patients must be instructed to always check the insulin label before each injection to avoid accidental mix-ups between Tresiba and other insulin products.
Patienterne skal instrueres i at genkende symptomer på alvorlige allergiske reaktioner.
Patients should be instructed in how to recognise symptoms of serious allergic reactions.
Patienterne skal instrueres i at injicere den fulde mængde af Simponi ifølge den detaljerede brugervejledning, som findes i indlægssedlen.
Patients should be instructed to inject the full amount of Simponi according to the comprehensive instructions for administration provided in the package leaflet.
Patienterne skal instrueres i at kontakte lægen, hvis:
Patients should be instructed to consult a doctor if:
Patienterne skal instrueres i at rapportere symptomer på infektion til deres læge under behandlingen.
During treatment, patients receiving Gilenya should be instructed to report symptoms of infection to their physician.
Patienterne skal instrueres i at sluge tabletterne hele (dvs. patienter bør ikke tygge, knække eller opløse tabletterne).
Patients should be instructed to swallow the tablets whole (i.e., patients should not chew, break or dissolve the tablets).
Patienterne skal instrueres i at søge lægehjælp, hvis de udvikler symptomer som åndenød, smerter i brystkassen eller hævelse i en arm eller et ben.
Patients should be instructed to seek medical care if they develop symptoms of thromboembolism such as shortness of breath, chest pain, arm or leg swelling.
Patienterne skal instrueres i at undgå sollys under behandling med Nevanac.
Patients should be instructed to avoid sunlight during treatment with NEVANAC.
Patienterne skal instrueres i at vaske hænder umiddelbart efter påføring af Picato samt mellem topikale påføringer, hvis to forskellige områder kræver forskellige styrker.
Patients should be instructed to wash their hands with soap and water, immediately after applying Picato, and between topical applications if two different areas require different strengths.
Patienterne skal instrueres i, at de ikke må starte med Viramune depottabletter, før et eventuelt udslæt opstået i den 14-dages optrapningsperiode med Viramune med umiddelbar frigivelse (oral suspension eller tabletter), er forsvundet.
Patients should be instructed that they should not begin Viramune prolonged-release tablets until any rash that has occurred during the 14-day lead-in period of Viramune immediate-release has resolved.
Patienterne skal instrueres i, at de ikke skal injicere en dobbelt dosis for at kompensere for den glemte dosis.
Patients should be instructed not to inject a double dose to make up for the forgotten dose.
Patienterne skal instrueres i, at insulin glargin-produkter med 100 enheder/ml og Toujeo ikke kan erstatte hinanden, og at dosisjusteringer skal foretages;
Patients need to be instructed that insulin glargine 100 units/ml products and Toujeo are not interchangeable and dose adjustments need to be made;
Patienterne skal instrueres i, hvordan præparatet administreres korrekt.
Patients should be instructed on how to administer the product correctly.
Patienterne skal instrueres om at VIRACEPT ikke helbreder en hiv-infektion, at de fortsat kan få infektioner eller andre sygdomme, som er relateret til hiv-sygdommen samt at det ikke er vist at VIRACEPT nedsætter risikoen for overførsel af hiv-sygdommen ved seksuel kontakt eller smittet blod.
Patients should be instructed that VIRACEPT is not a cure for HIV infection, that they may continue to develop infections or other illnesses associated with HIV disease, and that VIRACEPT has not been shown to reduce the risk of transmission of HIV disease through sexual contact or blood contamination.
Patienterne skal instrueres om at VIRACEPT ikke helbreder en hiv-infektion, at de fortsat kan få infektioner eller andre sygdomme, som er releteret til hiv-sygdommen samt at det ikke er vist, at VIRACEPT nedsætter risikoen for overførsel af hiv-sygdommen ved seksuel kontakt eller smittet blod.
Patients should be instructed that VIRACEPT is not a cure for HIV infection, that they may continue to develop infections or other illnesses associated with HIV disease, and that VIRACEPT has not been shown to reduce the risk of transmission of HIV disease through sexual contact or blood contamination.
Patienterne skal instrueres om straks at indberette kraftige, vedvarende og/eller tiltagende symptomer.
Patients should be advised to promptly report severe, persistent, and/or worsening symptoms.
Patienterne skal kende til potentielle risikofaktorer (hudfølsomhedstype og nedsat leverfunktion).
Patients should be aware of potential risk factors (skin phototype and hepatic impairment).
Patienterne skal kontrollere, at kontrolvinduet er grønt.
Patients should check that the control window is green.
Patienterne skal kontrolleres jævnligt af en læge, så den styrke af salmeterol/fluticasonpropionat-inhalatoren, de får, forbliver optimal, og denne må kun ændres af lægen.
Patients should be regularly reassessed by a doctor, so that the strength of the salmeterol/fluticasone propionate inhaler they are receiving remains optimal and is only changed on medical advice.
Patienterne skal monitoreres for svære infektioner, herunder sepsis og septisk shock.
Patients should be monitored for severe infections including sepsis and septic shock.
Patienterne skal monitoreres for tegn og symptomer på hypofysitis (inklusive hypofyseinsufficiens (hypopituitarisme) og sekundær binyrebarkinsufficiens), og andre årsager skal udelukkes.
Patients should be monitored for signs and symptoms of hypophysitis (including hypopituitarism and secondary adrenal insufficiency) and other causes excluded.
Patienterne skal monitoreres for udvikling eller forværring af proteinuri under behandlingen med ramucirumab.
Patients should be monitored for the development or worsening of proteinuria during ramucirumab therapy.
Patienterne skal monitoreres nøje for at sikre, at den laveste godkendte Aranesp-dosis til at opnå tilstrækkelig kontrol med symptomerne på anæmi anvendes, samtidigt med at en hæmoglobinkoncentration på mindre end eller lig med 12 g/dl (7,5 mmol/l) opretholdes.
Patients should be monitored closely to ensure that the lowest approved effective dose of Aranesp is used to provide adequate control of the symptoms of anaemia whilst maintaining a haemoglobin concentration below or at 12 g/dl (7.5 mmol/l).
Patienterne skal monitoreres nøje for at sikre, at der anvendes den laveste godkendte dosis erytropoiese-stimulerende stof (ESA) til at opnå tilstrækkelig kontrol med symptomerne på anæmi.
Patients should be monitored closely to ensure that the lowest approved dose of erythropoiesis- stimulating agent (ESA) is used to provide adequate control of the symptoms of anaemia.
Patienterne skal monitoreres nøje i omstillingsperioden fra buprenorphin eller methadon til buprenorphin/naloxon, idet der er modtaget indberetninger om abstinenssymptomer.
Patients should be clearly monitored during the switching period from buprenorphine or methadone to buprenorphine/naloxone since withdrawal symptoms have been reported.
Patienterne skal monitoreres nøje, når Bortezomib Hospira gives sammen med kraftige CYP3A4- hæmmere.
Patients should be closely monitored when given Bortezomib Hospira in combination with potent CYP3A4-inhibitors.
Patienterne skal monitoreres omhyggeligt for bivirkninger, når oral topotecan administreres samtidig med lægemidler, der hæmmer ABCB1 eller ABCG2 (se pkt.
Patients should be carefully monitored for adverse reactions when oral topotecan is administered with a drug known to inhibit ABCB1 or ABCG2 (see section 5.2).
Patienterne skal monitoreres omhyggeligt med hensyn til sikkerhed og effekt under behandling med Jakavi.
Patients should be carefully monitored with regard to safety and efficacy during Jakavi treatment.
Patienterne skal monitoreres omhyggeligt, når der gives bortezomib sammen med kraftige CYP3A4- hæmmere.
Patients should be closely monitored when given bortezomib in combination with potent CYP3A4 inhibitors.
Patienterne skal monitoreres omhyggeligt, når der gives bortezomib sammen med kraftige CYP3A4- hæmmere.
Patients should be closely monitored when given bortezomib in combination with potent CYP3A4-inhibitors.
Patienterne skal monitoreres tæt for bivirkninger, hvis der påbegyndes en samtidig behandling med en potent CYP2D6-hæmmer.
If concomitant treatment with a potent CYP2D6 inhibitor is initiated, the patient should be closely monitored for adverse reactions.
Patienterne skal monitores tæt, når behandlingen med dabrafenib genoptages efter en episode med pancreatitis.
Patients should be closely monitored when re-starting dabrafenib after an episode of pancreatitis.
Patienterne skal observeres for tegn og symptomer på leverdysfunktion, når Zinbryta anvendes sammen med andre hepatotoksiske lægemidler.
Patients should be observed for signs and symptoms of hepatic dysfunction when Zinbryta is used concomitantly with other hepatotoxic medicinal products.
Patienterne skal omhyggeligt evalueres for forekomst af SPM før og under behandlingen ved hjælp af standard- cancerscreening og indiceret behandling iværksættes.
Physicians should carefully evaluate patients before and during treatment using standard cancer screening for occurrence of SPM and institute treatment as indicated.
Patienterne skal oplyses om de tidlige tegn på overfølsomhed inkl. urticaria, trykken for brystet, hiven efter vejret, hypotension og anafylaxi.
Patients should be informed of the early signs of hypersensitivity reactions including urticaria, tightness of the chest, wheezing, hypotension, and anaphylaxis.
Patienterne skal overvåges for forekomst af non-melanom hudcancer.
Monitor patients for the appearance of non-melanoma skin cancer.
Patienterne skal overvåges for nyopståede abdominalsmerter eller forværring af abdominalsmerter, som kan stråle ud til ryg eller skulder, med eller uden kvalme og opkastning.
Patients should be monitored for new or worsening abdominal pain, that may radiate to the back or shoulder , with or without nausea and vomiting.
Patienterne skal overvåges nøje for at sikre, at der anvendes den lavest godkendte Nespo-dosis til at kontrollere symptomerne på anæmi i tilstrækkelig grad.
Patients should be monitored closely to ensure that the lowest approved dose of Nespo is used to provide adequate control of the symptoms of anaemia.
Patienterne skal rådes til at henvende sig omgående til deres læge med eventuelle symptomer, der tyder på infektion, så som feber, ondt i halsen og influenzalignende symptomer.
Patients should be advised to report immediately to their physician any symptoms indicative of infection such as fever, sore throat and flu-like symptoms.
Patienterne skal rådes til at læse instruktionerne omhyggeligt.
Patients should be advised to carefully read them.
Patienterne skal rådes til ikke at føre motorkøretøj og betjene maskiner, hvis de oplever konfusion, somnolens eller andre bivirkninger, der kan påvirke deres evne til at føre motorkøretøj eller betjene maskiner.
Patients should be advised not to drive or operate machines if they experience confusion or somnolence or other adverse reactions which can impair their ability to drive or operate machines.